Prospective Real-world Registry Describing Treatment Regimens

Study Overview
=================
Brief Summary
-----------------
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.

Detailed Description
-----------------
Coordinator of project has strong expertise in cardiovascular research and especially in ACS, PCI and antiplatelet therapy. The group led by pr Bonello has published several articles (appendix 3) including the VASP studies which have been presented at major cardiologic congresses (late breaking trials ACC 2007, AHA 2008, TCT 2011, EuroPCR 2010) including physicians and biologists. The group is composed of international experts in this research field (Pr Bonello, Pr Cuisset, Dr Barragan, Pr Lemesle). Additionally, coordinator center has a strong expertise in clinical research and a methodological support will be provided by the Clinical Research Platform of the AP-HM (responsible: Prof. Pascal Auquier, medical referent: Dr Karine Baumstarck). The project brings together investigators that have been previously involved in many clinical studies in the field of ACS and PCI. In particular they have joined forces on multicenter trials leaded by the cardiology department of the Hôpital Universitaire Nord de Marseille (the VASP studies, the Early clinical trial) and they have regular meetings to share scientific data and research program design and advancement. There is a good capacity and ability of recruitment by the partner centers. The procedures to perform in this project are very simple and the disease is frequent. These are good criteria for the feasibility.

Official Title
-----------------
Real-world Prospective Registry to Describe the Current Treatment Patterns With Oral Anticoagulant and Antiplatelet Agents Association in Patients With Atrial Fibrillation and Undergoing Percutaneous Coronary Intervention

Conditions
-----------------
Subject Under Anticoagulant

Intervention / Treatment
-----------------
* Other: an observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The eligible subjects must meet all of the following criteria: Man or woman 18 years old or over Subject requiring percutaneous coronary intervention according to physician's and with AF requiring chronic anticoagulation by dual therapy or triple therapy; Subject with pulmonary embolism risk score > 1 for men and ≥ 1 for women in CHA2DS2-VASc classification Subject having declare its non-opposition to study participation Exclusion Criteria: Child-bearing potential (1 year post-menopausal, contraceptive or surgically sterile) Lactation No health insurance Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| dual therapy<br>including 1 antiplatelet treatment aspirin or clopidogrel associated with 1 anticoagulant treatment VKA or NOAC. | Other: an observational study<br>* this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.<br>|
| triple therapy<br>including 2 antiplatelet treatments (aspirin and clopidogrel) associated with 1 anticoagulant treatment VKA or NOAC. In VKA class, 2 different drugs are commonly prescribed: warfarin and fluidinione. In NOAC class, 3 different drugs are commonly prescribed: rivaroxaban, apixaban, dabigatran. | Other: an observational study<br>* this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of patients treated after PCI with each drug class. |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The type, the daily dosage and the duration of each drug class |  | 18 MONTHS | 
| The type, the daily dosage and the duration of each drug combination |  | 18 MONTHS | 
| tthe type of bleeding events according TIMI classification1 for each drug |  | 18 MONTHS | 
| The major adverse cardiovascular events (MACE) |  | 18 months |